Pyxis Oncology (PYXS) Net Cash Flow (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Net Cash Flow data on file, last reported at $6.5 million in Q4 2025.

• Net Cash Flow for Q4 2025 came in at $6.5 million, down 12.32% year-over-year; the trailing twelve-month figure through Dec 2025 was -$4.0 million (down 140.62% YoY), and the FY2025 annual result was -$4.1 million, down 141.3% from the prior year.
• Net Cash Flow improved to $6.5 million in Q4 2025 per PYXS's latest filing, from -$1.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $142.7 million in Q4 2021 and troughed at -$126.2 million in Q1 2023.
• A 5-year average of $132400.0 and a median of -$5.9 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2021 and 2022: Net Cash Flow surged 4608.24% in 2021, then slumped 1417.86% in 2022.
• A 5-year view of Net Cash Flow shows it stood at $142.7 million in 2021, then sank by 113.48% to -$19.2 million in 2022, then soared by 73.75% to -$5.1 million in 2023, then jumped by 246.84% to $7.4 million in 2024, then retreated by 12.32% to $6.5 million in 2025.
• Business Quant data shows PYXS's Net Cash Flow at $6.5 million in Q4 2025, -$1.8 million in Q3 2025, and -$2.0 million in Q2 2025.